BEDFORD, Mass., Feb. 26, 2014 /PRNewswire/ -- Hologic, Inc.
(Hologic or the Company) (NASDAQ: HOLX), a leading developer,
manufacturer and supplier of premium diagnostic products, medical
imaging systems and surgical products with an emphasis on serving
the healthcare needs of women, announced today that the Company
completed a refinancing of its senior secured tranche B term loan
facility (Existing Term Loan B) under the Company's Credit and
Guaranty Agreement (Credit Agreement) dated August 1, 2012.
On February 26, 2014, the Company
and several of its domestic subsidiaries (Guarantors), together
with Goldman Sachs Bank USA, as
administrative and collateral agent, and the lenders party thereto
entered into Refinancing Amendment No. 3 (Credit Agreement
Amendment 3) to the Credit Agreement.
The Credit Agreement Amendment 3 evidences, among other things,
the refinancing of the Company's Existing Term Loan B with a
maturity date of August 1, 2019, with
a new senior secured tranche B term loan facility (New Term Loan B)
with an issue price of 99.875% of the principal amount of the
Existing Term Loan B (subject also to the prepayment referenced
below). The Credit Agreement Amendment 3 will result in up to a 50
basis point reduction in the interest rate on the New Term Loan B
as of the Credit Agreement Amendment 3 closing date (from 2.75%
plus LIBOR with a 1.00% floor to 2.50% plus LIBOR with a 0.75%
floor). In addition, the Company voluntarily prepaid $25 million of the New Term Loan B on
February 26, 2014. Immediately
following this prepayment, the principal amount outstanding on the
New Term Loan B is approximately $1.15
billion.
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems, and
surgical products, with an emphasis on serving the healthcare needs
of women. The Company operates four core business units focused on
breast health, diagnostics, GYN surgical and skeletal health. With
a comprehensive suite of technologies and a robust research and
development program, Hologic is committed to improving lives. The
Company is headquartered in Massachusetts. For more information, visit
www.hologic.com.
Hologic and associated logos are trademarks and/or registered
trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Investor Relations
and Media Contacts:
|
|
Deborah R.
Gordon
|
Al Kildani
|
Vice President,
Investor Relations
|
Senior Director,
Investor Relations
|
(781)
999-7716
|
(858)
410-8653
|
deborah.gordon@hologic.com
|
al.kildani@hologic.com
|
SOURCE Hologic, Inc.